Cover Image
市場調查報告書

發炎 - 開發中產品分析

Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 257909
出版日期 內容資訊 英文 1103 Pages
訂單完成後即時交付
價格
Back to Top
發炎 - 開發中產品分析 Inflammation - Pipeline Review, H1 2014
出版日期: 2014年06月30日 內容資訊: 英文 1103 Pages
簡介

發炎是損傷細胞和刺激物開始消除病原菌等有害刺激物及治癒流程的生物性反應。症狀有疼痛、皮膚發紅、發燒的腫、發燒、鼻塞、頭痛、呼吸障礙(氣喘)、體液儲存、凝血等,發病要素有鈍器外傷、傷病、慢性健康障礙等。治療使用NSAIDS(非類固醇系抗發炎劑),皮質類固醇,ImSAID等。

本報告提供發炎之治療藥開發情形調查分析,提供您開發中產品概要、臨床實驗的各階段產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

發炎概要

治療藥的開發

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

治療藥的評估

藥物簡介

開發中產品的最新趨勢

暫停中的計劃

成為了開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5069IDB

Summary

Global Markets Direct's, 'Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Inflammation Overview
  • Therapeutics Development
  • Inflammation - Therapeutics under Development by Companies
  • Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Inflammation - Pipeline Products Glance
  • Inflammation - Products under Development by Companies
  • Inflammation - Products under Investigation by Universities/Institutes
  • Inflammation - Companies Involved in Therapeutics Development
  • Inflammation - Therapeutics Assessment
  • Drug Profiles
  • Inflammation - Recent Pipeline Updates
  • Inflammation - Dormant Projects 1
  • Inflammation - Discontinued Products 1
  • Inflammation - Product Development Milestones 1
  • Appendix 1

List of Tables

  • Number of Products under Development for Inflammation, H1 2014
  • Number of Products under Development for Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Development by Companies, H1 2014 (Contd..2)
  • Number of Products under Development by Companies, H1 2014 (Contd..3)
  • Number of Products under Development by Companies, H1 2014 (Contd..4)
  • Number of Products under Development by Companies, H1 2014 (Contd..5)
  • Number of Products under Development by Companies, H1 2014 (Contd..6)
  • Number of Products under Development by Companies, H1 2014 (Contd..7)
  • Number of Products under Development by Companies, H1 2014 (Contd..8)
  • Number of Products under Development by Companies, H1 2014 (Contd..9)
  • Number of Products under Development by Companies, H1 2014 (Contd..10)
  • Number of Products under Development by Companies, H1 2014 (Contd..11)
  • Number of Products under Development by Companies, H1 2014 (Contd..12)
  • Number of Products under Development by Companies, H1 2014 (Contd..13)
  • Number of Products under Development by Companies, H1 2014 (Contd..14)
  • Number of Products under Development by Companies, H1 2014 (Contd..15)
  • Number of Products under Development by Companies, H1 2014 (Contd..16)
  • Number of Products under Development by Companies, H1 2014 (Contd..17)
  • Number of Products under Development by Companies, H1 2014 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4)
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Comparative Analysis by Unknown Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Products under Development by Companies, H1 2014 (Contd..2)
  • Products under Development by Companies, H1 2014 (Contd..3)
  • Products under Development by Companies, H1 2014 (Contd..4)
  • Products under Development by Companies, H1 2014 (Contd..5)
  • Products under Development by Companies, H1 2014 (Contd..6)
  • Products under Development by Companies, H1 2014 (Contd..7)
  • Products under Development by Companies, H1 2014 (Contd..8)
  • Products under Development by Companies, H1 2014 (Contd..9)
  • Products under Development by Companies, H1 2014 (Contd..10)
  • Products under Development by Companies, H1 2014 (Contd..11)
  • Products under Development by Companies, H1 2014 (Contd..12)
  • Products under Development by Companies, H1 2014 (Contd..13)
  • Products under Development by Companies, H1 2014 (Contd..14)
  • Products under Development by Companies, H1 2014 (Contd..15)
  • Products under Development by Companies, H1 2014 (Contd..16)
  • Products under Development by Companies, H1 2014 (Contd..17)
  • Products under Development by Companies, H1 2014 (Contd..18)
  • Products under Development by Companies, H1 2014 (Contd..19)
  • Products under Development by Companies, H1 2014 (Contd..20)
  • Products under Development by Companies, H1 2014 (Contd..21)
  • Products under Development by Companies, H1 2014 (Contd..22)
  • Products under Development by Companies, H1 2014 (Contd..23)
  • Products under Development by Companies, H1 2014 (Contd..24)
  • Products under Development by Companies, H1 2014 (Contd..25)
  • Products under Development by Companies, H1 2014 (Contd..26)
  • Products under Development by Companies, H1 2014 (Contd..27)
  • Products under Development by Companies, H1 2014 (Contd..28)
  • Products under Development by Companies, H1 2014 (Contd..29)
  • Products under Investigation by Universities/Institutes, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..5)
  • Products under Investigation by Universities/Institutes, H1 2014 (Contd..6)
  • Inflammation - Pipeline by Bristol-Myers Squibb Company, H1 2014
  • Inflammation - Pipeline by Johnson & Johnson, H1 2014
  • Inflammation - Pipeline by Boehringer Ingelheim GmbH, H1 2014
  • Inflammation - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
  • Inflammation - Pipeline by Amgen Inc., H1 2014
  • Inflammation - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by GlaxoSmithKline plc, H1 2014
  • Inflammation - Pipeline by Genentech, Inc., H1 2014
  • Inflammation - Pipeline by Nektar Therapeutics, H1 2014
  • Inflammation - Pipeline by Agenus, Inc., H1 2014
  • Inflammation - Pipeline by MedImmune, LLC, H1 2014
  • Inflammation - Pipeline by Gilead Sciences, Inc., H1 2014
  • Inflammation - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
  • Inflammation - Pipeline by Merck & Co., Inc., H1 2014
  • Inflammation - Pipeline by Ablynx NV, H1 2014
  • Inflammation - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
  • Inflammation - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014
  • Inflammation - Pipeline by Euroscreen S.A., H1 2014
  • Inflammation - Pipeline by Novo Nordisk A/S, H1 2014
  • Inflammation - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014
  • Inflammation - Pipeline by Piramal Enterprises Limited, H1 2014
  • Inflammation - Pipeline by Amorepacific Corporation, H1 2014
  • Inflammation - Pipeline by Astellas Pharma Inc., H1 2014
  • Inflammation - Pipeline by Kowa Company, Ltd., H1 2014
  • Inflammation - Pipeline by LEO Pharma A/S, H1 2014
  • Inflammation - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014
  • Inflammation - Pipeline by Pfizer Inc., H1 2014
  • Inflammation - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
  • Inflammation - Pipeline by UCB S.A., H1 2014
  • Inflammation - Pipeline by Zydus Cadila Healthcare Limited, H1 2014
  • Inflammation - Pipeline by Exelixis, Inc., H1 2014
  • Inflammation - Pipeline by Celgene Corporation, H1 2014
  • Inflammation - Pipeline by Bayer AG, H1 2014
  • Inflammation - Pipeline by Incyte Corporation, H1 2014
  • Inflammation - Pipeline by Merck KGaA, H1 2014
  • Inflammation - Pipeline by Evotec AG, H1 2014
  • Inflammation - Pipeline by Harbor Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by Star Scientific, Inc., H1 2014
  • Inflammation - Pipeline by Genfit SA, H1 2014
  • Inflammation - Pipeline by Can-Fite BioPharma Ltd., H1 2014
  • Inflammation - Pipeline by Karo Bio AB, H1 2014
  • Inflammation - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by TG Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Lpath, Inc., H1 2014
  • Inflammation - Pipeline by Lupin Limited, H1 2014
  • Inflammation - Pipeline by Basilea Pharmaceutica AG, H1 2014
  • Inflammation - Pipeline by NicOx S.A., H1 2014
  • Inflammation - Pipeline by Compugen Ltd., H1 2014
  • Inflammation - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014
  • Inflammation - Pipeline by Palatin Technologies, Inc., H1 2014
  • Inflammation - Pipeline by Pharmaxis Limited, H1 2014
  • Inflammation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by Portola Pharmaceuticals, Inc., H1 2014
  • Inflammation - Pipeline by CSL Limited, H1 2014
  • Inflammation - Pipeline by Cytomedix, Inc., H1 2014
  • Inflammation - Pipeline by Array BioPharma Inc., H1 2014
  • Inflammation - Pipeline by Dynavax Technologies Corporation, H1 2014
  • Inflammation - Pipeline by XOMA Corporation, H1 2014
  • Inflammation - Pipeline by MorphoSys AG, H1 2014
  • Inflammation - Pipeline by BioInvent International AB, H1 2014
  • Inflammation - Pipeline by Transgene SA, H1 2014
  • Inflammation - Pipeline by Progen Pharmaceuticals Limited, H1 2014
  • Inflammation - Pipeline by JW Pharmaceutical Corporation, H1 2014
  • Inflammation - Pipeline by Galectin Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014
  • Inflammation - Pipeline by Biotie Therapies Corp., H1 2014
  • Inflammation - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014
  • Inflammation - Pipeline by Galapagos NV, H1 2014
  • Inflammation - Pipeline by Synta Pharmaceuticals Corp., H1 2014
  • Inflammation - Pipeline by BioAlliance Pharma SA, H1 2014
  • Inflammation - Pipeline by Innate Pharma SA, H1 2014
  • Inflammation - Pipeline by MetrioPharm AG, H1 2014
  • Inflammation - Pipeline by Proteo, Inc., H1 2014
  • Inflammation - Pipeline by Verona Pharma Plc, H1 2014
  • Inflammation - Pipeline by Angelini Group, H1 2014
  • Inflammation - Pipeline by Affitech A/S, H1 2014
  • Inflammation - Pipeline by Debiopharm International S.A., H1 2014
  • Inflammation - Pipeline by Chroma Therapeutics Ltd., H1 2014
  • Inflammation - Pipeline by Advinus Therapeutics Ltd., H1 2014
  • Inflammation - Pipeline by CJ CheilJedang Corp., H1 2014
  • Inflammation - Pipeline by Antitope Ltd., H1 2014
  • Inflammation - Pipeline by Axxam SpA, H1 2014
  • Inflammation - Pipeline by INSYS Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Aurigene Discovery Technologies Limited, H1 2014
  • Inflammation - Pipeline by Alba Therapeutics Corporation, H1 2014
  • Inflammation - Pipeline by AcurePharma AB, H1 2014
  • Inflammation - Pipeline by Ambit Biosciences Corporation, H1 2014
  • Inflammation - Pipeline by Viron Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Immupharma Plc, H1 2014
  • Inflammation - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014
  • Inflammation - Pipeline by Molecular Partners AG, H1 2014
  • Inflammation - Pipeline by Physica Pharma, H1 2014
  • Inflammation - Pipeline by Acceleron Pharma, Inc., H1 2014
  • Inflammation - Pipeline by Lipicard Technologies Limited, H1 2014
  • Inflammation - Pipeline by Conaris Research Institute AG, H1 2014
  • Inflammation - Pipeline by Hutchison MediPharma Limited, H1 2014
  • Inflammation - Pipeline by Affibody AB, H1 2014
  • Inflammation - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014
  • Inflammation - Pipeline by Aquinox Pharmaceuticals Inc., H1 2014
  • Inflammation - Pipeline by Argos Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by Aegera Therapeutics Inc., H1 2014
  • Inflammation - Pipeline by Anchor Therapeutics, Inc., H1 2014
  • Inflammation - Pipeline by AnaptysBio, Inc., H1 2014
  • Inflammation - Pipeline by Allozyne, Inc., H1 2014
  • Inflammation - Pipeline by Funxional Therapeutics Ltd, H1 2014

List of Figures

  • Number of Products under Development for Inflammation, H1 2014
  • Number of Products under Development for Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top